Neumann Capital Management
Neumann Capital
elsewhere's corpus does not cover Neumann Capital Management as a subject. The only material that names it is a 2022 co-investment in Helixon's Series A alongside 5Y Capital, Gaorong Capital, and others , which gives no information about the firm's own identity, founding, strategy, or team.
AI-generated — may contain errors, please verify.
Neumann Capital ManagementFund
Neumann Capital
渲染中…
Mentioned in 3 articles
Coverage
From Medallion to AI-Native Asset Management: GIM Closes Three Funding Rounds
Will a Century-Old Asset Management Industry Be Rewritten by AI?
5Y News | Helixon Pharma Closes Nearly 500 Million Yuan Series A to Deepen AI-Powered Drug Discovery
Building a life-science platform powered by artificial intelligence.
Helixon Closes Nearly RMB 500 Million Series A Round, AI-Powered Large-Molecule Drug Discovery
We've developed a suite of groundbreaking algorithms for protein drug design and modeling.
